• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

Professional Introduction to 4-(Cyclohexylsulfamoyl)benzoic acid (CAS No. 6314-70-1)

4-(Cyclohexylsulfamoyl)benzoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 6314-70-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic research. This compound belongs to the class of sulfonamides, which are widely recognized for their diverse biological activities and therapeutic potential. The structural motif of benzoic acid, combined with a cyclohexylsulfamoyl group, imparts unique physicochemical properties that make it a valuable scaffold for drug discovery and development.

The molecular structure of 4-(Cyclohexylsulfamoyl)benzoic acid consists of a benzoic acid core substituted at the para position with a sulfamoyl group linked to a cyclohexyl ring. This configuration contributes to its solubility characteristics and interaction profiles with biological targets. The cyclohexyl moiety enhances lipophilicity, while the sulfamoyl group introduces polar interactions, making this compound a promising candidate for modulating enzyme activity and receptor binding.

In recent years, there has been growing interest in sulfonamide derivatives as pharmacophores due to their ability to engage with various biological pathways. Studies have demonstrated that compounds containing the sulfamoyl moiety exhibit inhibitory effects on enzymes such as carbonic anhydrase, dihydrofolate reductase, and various proteases. The benzoic acid component further extends its potential applications by providing a rigid aromatic platform for further derivatization and optimization.

One of the most compelling aspects of 4-(Cyclohexylsulfamoyl)benzoic acid is its utility in medicinal chemistry as a building block for novel therapeutics. Researchers have leveraged this scaffold to design molecules with enhanced selectivity and reduced toxicity. For instance, modifications at the cyclohexyl ring or the sulfamoyl group have led to compounds with improved pharmacokinetic profiles, making them more suitable for clinical translation.

Recent advancements in computational chemistry have accelerated the process of identifying promising derivatives of 4-(Cyclohexylsulfamoyl)benzoic acid. Machine learning models trained on large datasets of bioactive compounds have been employed to predict binding affinities and metabolic stability, enabling rational design of next-generation candidates. These computational approaches complement traditional high-throughput screening methods, providing a more efficient pipeline for drug discovery.

The synthesis of 4-(Cyclohexylsulfamoyl)benzoic acid typically involves multi-step organic transformations, starting from commercially available precursors such as benzoic acid and cyclohexyl isocyanate or cyclohexylamine derivatives. Advances in synthetic methodologies have improved yield and purity, making large-scale production feasible for both research and industrial applications. Catalytic processes and green chemistry principles have also been integrated into synthetic routes to minimize environmental impact.

In the realm of preclinical research, 4-(Cyclohexylsulfamoyl)benzoic acid has been investigated for its potential in treating inflammatory diseases, neurodegenerative disorders, and metabolic conditions. Preclinical studies suggest that derivatives of this compound may modulate inflammatory pathways by inhibiting key cytokines or enzymes involved in the immune response. Additionally, its ability to cross the blood-brain barrier has opened avenues for exploring treatments targeting central nervous system disorders.

The role of 4-(Cyclohexylsulfamoyl)benzoic acid in combinatorial chemistry and library synthesis cannot be overstated. Its structural features allow for facile introduction of diverse functional groups, enabling the creation of large libraries of compounds for screening against various disease targets. Such libraries are instrumental in identifying lead compounds that can be further optimized through structure-activity relationship (SAR) studies.

Regulatory considerations play a crucial role in the development and commercialization of derivatives based on 4-(Cyclohexylsulfamoyl)benzoic acid. Compliance with Good Manufacturing Practices (GMP) ensures that pharmaceutical-grade materials meet stringent quality standards. Additionally, toxicological assessments are essential to evaluate potential side effects before human trials can commence. These regulatory milestones are critical for ensuring patient safety and efficacy.

The future prospects of 4-(Cyclohexylsulfamoyl)benzoic acid are promising, with ongoing research exploring novel applications in personalized medicine and targeted therapy. Innovations in drug delivery systems, such as nanoparticles and prodrugs, may enhance the bioavailability and therapeutic efficacy of derivatives derived from this compound. Furthermore, collaborations between academic institutions and pharmaceutical companies are likely to yield breakthroughs in understanding its full potential.

In conclusion,4-(Cyclohexylsulfamoyl)benzoic acid (CAS No. 6314-70-1) represents a significant advancement in pharmaceutical chemistry due to its versatile structure and wide-ranging biological activities. Its incorporation into drug discovery pipelines has yielded promising candidates for treating diverse diseases, while ongoing research continues to uncover new therapeutic applications. As computational tools and synthetic methodologies evolve，the utility of this compound is expected to expand，further solidifying its importance in modern medicine.

• 99987-05-0(4-(tert-Butylamino)sulfonylbenzoic Acid)
• 918666-95-2(Benzoic acid, 4-[(phenylpropylamino)sulfonyl]-)
• 10252-65-0(4-(Propylamino)sulfonylbenzoic Acid)
• 716358-46-2(3-(Isopropylamino)sulfonylbenzoic acid)
• 7326-75-2(3-(N-Propylsulfamoyl)benzoic acid)
• 10252-66-1(4-(Propan-2-yl)sulfamoylbenzoic Acid)
• 91642-71-6(1,3-Benzenedicarboxylicacid, 5-[(butylamino)sulfonyl]-)
• 7326-76-3(3-(Butan-2-yl)sulfamoylbenzoic Acid)
• 852933-50-7(3-(Cyclopropylsulfamoyl)benzoic acid)
• 6306-16-7(Benzoic acid,4-[(butylamino)sulfonyl]-)